GLP » Trang Công Nghệ | Trangcongnghe.vn

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development

Globe Newswire

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development

Globenewswire -

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Globe Newswire

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Globenewswire -

Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

Globe Newswire

Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

Globenewswire -

Arla Foods Ingredients Targets GLP-1 Companion Nutrition at Vitafoods Europe

Globe Newswire

Arla Foods Ingredients Targets GLP-1 Companion Nutrition at Vitafoods Europe

Globenewswire -

WeightWatchers Advances International Growth With Strategic Leadership Appointment

Globe Newswire

WeightWatchers Advances International Growth With Strategic Leadership Appointment

Globenewswire -